Clinical trials: Oral Neoplasm
Hematologic Malignancy
Oral Complications in Hematological Malignancies
The aim of this study was to evaluate the prevalence and types of oral complications found in patients diagnosed with haematological malignancy
- Trial name
- NCT05758207
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Tumors
Study Evaluating SKI-606 in Subject With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated…
- Trial name
- NCT01001936
- Testing
- SKI-606
- Volunteers
- 28 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Salivary Gland Neoplasms
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or…
- Trial name
- YATAGARASU (NCT04325828)
- Testing
- Apalutamide, GnRH Agonist
- Where
- 7 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Janssen Pharmaceutical K.K.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Oral Leukoplakia
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12…
- Trial name
- NCT05727761
- Testing
- pioglitazone-metformin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota
Colorectal Cancer
Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects
This study is to investigate the effect of various modified low volume polyethylene glycol (PEG) 3350 and ascorbic acid/ascorbate (PEG+ASC)-based gut cleansing solutions on stool output in healthy subjects.
- Trial name
- OUT (NCT01834742)
- Testing
- NER1006, Moviprep
- Where
- 2 sites in Romania
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Norgine
Erythroplakia, Leukoplakia
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions.
- Conditions
- Erythroplakia, Leukoplakia, Oral Cavity Carcinoma, Proliferative Verrucous Leukoplakia
- Trial name
- NCT05536037
- Testing
- Metformin, Biopsy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
This is a monocentric, non-randomized, prospective, in silico feasibility study conducted by Strasbourg Europe Cancerology Institute.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- OPPIDOM (NCT04801472)
- Testing
- Optimisation of dental implant sites protection from irradiation
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Cervical Dysplasia
Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia
To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.
- Trial name
- NCT00212381
- Testing
- di indolylmethane (DIM), Red rice bran
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- New York Presbyterian Hospital
Oral Mucositis
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
The purpose of the study is to evaluate the efficacy, safety and tolerability of topically administered AG013 compared to placebo for reducing Oral Mucositis (OM) in patients undergoing chemoradiation for the treatment of head…
- Trial name
- NCT03234465
- Testing
- AG013
- Where
- 50 sites in United States, Belgium and 2 more
- Volunteers
- 200 people
- Sponsor
- Oragenics, Inc.
Cervical Cancer, Stage IIB
Curcumin in Advanced Cervical Cancer
Determine the efficacy and safety of turmeric in the treatment of patients with advanced cervical cancer. Efficacy will be determined through radiological and histopathological criteria through the rate of response to treatment…
- Trial name
- NCT04294836
- Testing
- Curcumin
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Tongue Neoplasms, Tongue Cancer
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery.
- Conditions
- Tongue Neoplasms, Tongue Cancer, Oral Cancer
- Trial name
- PGSRT (NCT02584270)
- Testing
- Palatal Augmentation Prosthesis (PAP), Articulation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic…
- Trial name
- NCT06126731
- Testing
- Enzalutamide 40mg, Amoxicillin 500mg, Metronidazole 400mg
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Institute of Cancer Research, United Kingdom
GI Carcinoma, GI Disorders
Phase 2 Study of NX9 for Delineation of Bowel Anatomy
This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast followed by CT with NX9 and…
- Trial name
- NCT04789200
- Testing
- NX9 Oral Contrast Agent
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Nextrast, Inc.
Oral Mucositis, Chemotherapy-induced Oral Mucositis
Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis
Oral mucositis is a frequent and often debilitating complication of radiotherapy and chemotherapy, particularly in patients treated for head and neck cancers.
- Conditions
- Oral Mucositis, Chemotherapy-induced Oral Mucositis, Head and Neck Neoplasms
- Trial name
- OZOMUC (NCT07491536)
- Testing
- Gas Ozone Therapy, Biomimetic Oral Care Regimen
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Pavia
Carcinoma, Non-Small-Cell Lung
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
- Trial name
- NCT02182232
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Background: The new drug BMN 673 (talazoparib) has been shown to fight tumor cells in animals and some people. It is a poly (ADP-ribose) polymerase (PARP) inhibitor.
- Trial name
- NCT02326844
- Testing
- BMN 673 (talazoparib)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Recurrent Bladder Cancer
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
The purpose of this study is to assess the effectiveness of erdafitinib in people with non-muscle invasive bladder cancer (NMIBC) that has come back after standard treatment, such as Bacillus Calmette-Guerin (BCG) or chemotherapy…
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
- Trial name
- NCT04917809
- Testing
- Erdafitinib
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have recurrent or…
- Trial name
- NCT00017498
- Testing
- gemcitabine hydrochloride
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oral Mucositis
Ozone Therapy for Cancer Therapy-Related Oral Mucositis
This retrospective observational study will evaluate clinical data already available from adult cancer patients who developed cancer therapy-related oral mucositis during radiotherapy and/or chemotherapy and who were managed in…
- Trial name
- OMUC-O3 (NCT07638904)
- Testing
- Combined Ozone-Based Oral Care Protocol
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Pavia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.